Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling, general and administrative | 150,697 | 103,013 | 287,126 | 188,008 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations before other income (expense) | (19,908) | (22,184) | (26,030) | (48,464) |
| Other income (expense): | ||||
| Interest income | 3,698 | 4,229 | 7,420 | 7,683 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s SG&A?
- Tarsus Pharmaceuticals, Inc. (TARS) reported SG&A of $150.7M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s SG&A increased by 46.3% year-over-year, from $103.01M to $150.7M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s SG&A has grown at a 111.8% compound annual growth rate (CAGR), from $44.95M to $427.32M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude